Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Traws Pharma ( (TRAW) ).
On November 13, 2025, Traws Pharma announced its financial results for the quarter ending September 30, 2025, highlighting significant cost reductions and the acquisition of intellectual property assets. The company is advancing its Phase 2 studies for ratutrelvir, a potential COVID-19 therapy, and tivoxavir marboxil for bird flu and seasonal flu, both representing substantial market opportunities. The company also reported management updates and a decrease in net loss compared to the previous year, indicating a strategic shift towards antiviral programs and partnerships for legacy oncology assets.
The most recent analyst rating on (TRAW) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to address critical threats from respiratory viral diseases. The company is working on antiviral programs, including treatments for COVID-19, bird flu, and seasonal flu, with a market focus on multi-billion dollar opportunities in the U.S.
Average Trading Volume: 179,566
Technical Sentiment Signal: Sell
Current Market Cap: $15.25M
Learn more about TRAW stock on TipRanks’ Stock Analysis page.